 SOUTH SAN FRANCISCO, Calif., July 12, 2022 GLOBE NEWSWIRE -- Sutro Biopharma, Inc. Sutro or the Company NASDAQ: STRO, a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates ADCs, today announced that management will host a virtual research forum in which it will unveil the next product candidate, discuss immunostimulatory ADCs iADCs as a novel modality, and highlight recent enhancement to its cell-free manufacturing platform. 